BAE Systems’ Norway Frigate Win Hits a UK Navy Bottleneck as Shares Slip

BAE Systems’ Norway Frigate Win Hits a UK Navy Bottleneck as Shares Slip

April 24, 2026

London, April 24, 2026, 14:56 (BST)

BAE Systems plc’s involvement in Britain’s £10 billion Norway frigate contract is under the microscope again. A UK defence minister has acknowledged that Royal Navy frigate slots were given up to Oslo and, so far, there are no new UK orders to offset the loss. Luke Pollard, responding in writing on Wednesday, confirmed “a number” of slots had been ceded. He added that the “delta”—the shortfall—will be addressed in the government’s 10-year Defence Investment Plan.

The Clyde program isn’t simply about exports anymore. BAE’s Glasgow yards are set to overhaul the Royal Navy and assemble vessels for Norway as well—part of an allied North Atlantic effort focused on anti-submarine missions and safeguarding key infrastructure.

BAE was trading 1.8% lower at 2,043 pence as of 14:55 BST. Across Europe, aerospace and defence names also dropped—off 2.8% on Friday—as investors pulled back from risk. All of this lands amid an ongoing procurement debate, challenging the defence-stock rally seen earlier this year.

Late Thursday, The Times reported that Norway has been handed the three UK frigates that hadn’t yet entered production—stoking fresh worries about Britain’s pace in swapping out aging Type 23 vessels. According to the paper, the first UK Type 26 isn’t due until 2028, and the rest of the program drags out well into the mid-2030s.

The government isn’t budging—at least for now. Pollard, speaking in the Commons last week, guaranteed at least eight Type 26 frigates are on tap for the Royal Navy. He also noted ongoing discussions with Norway over build slots, arguing the agreement would keep Clyde shipyards busy “for many years to come.” UK Defence Journal

The Type 26 frigate specializes in anti-submarine warfare, designed chiefly for hunting and neutralizing underwater threats. BAE describes the UK project as an eight-ship replacement for the Royal Navy’s ageing Type 23 fleet. Norway, for its part, has also declared intentions to buy a minimum of five Type 26 vessels through the UK partnership.

BAE still looks solid from a financial standpoint. Back in February, the company reported an £83.6 billion order backlog, set out a sales growth target of 7% to 9% for 2026, and projected underlying EBIT—operating profit before interest and tax—would increase by 9% to 11%. It’s also aiming to pay a final dividend of 22.8 pence to shareholders registered as of April 24.

Charles Woodburn, chief executive, called Norway’s move a show of faith in Britain’s industrial base, arguing it underscored Oslo’s trust in BAE’s capacity to provide what he called a “superior anti-submarine warfare platform.” Defence Secretary John Healey, for his part, noted back then that the two navies would “work as one” on NATO’s northern flank. The Guardian

BAE emerged ahead of competitors in Norway’s high-stakes frigate competition, outpacing offers from France, Germany, and the U.S. According to Naval News, France put forward the FDI, Germany the F127, and the U.S. the Constellation-class—all ultimately losing out to Britain’s Type 26, Oslo’s final pick.

BAE’s risk isn’t about losing work—it’s about timing. If the UK holds off on new orders until the Defence Investment Plan is sorted, future Royal Navy deliveries could slip, putting ministers on the spot to explain a smaller fleet in the short term. Meanwhile, BAE’s export wins might spark political debate over production capacity.

That’s the kicker with Norway’s deal: Clyde yards stay humming and BAE’s export pipeline looks stronger, yet every build slot is now out in the open. In defence, sometimes you want that. Still, it’s a problem, no question.

Stock Market Today

  • Syntara Shares Plummet Despite FDA Trial Pathway Clarity on Myelofibrosis Drug
    June 10, 2026, 5:03 PM EDT. Syntara (ASX:SNT) sees its shares halved after the FDA required a separate phase IIb trial for its myelofibrosis drug, amsulostat, delaying the registration phase III study. CEO Gary Phillips states the market misinterpreted the FDA's guidance as a clinical failure, although the drug isn't failing in trials. The company, formerly Pharmaxis, shifted focus to diseases involving fibrosis and inflammation with its LOX enzyme-targeting compounds. Myelofibrosis, a bone marrow scarring disease with limited treatment options, affects approximately 500,000 globally. Syntara aims to deliver disease-modifying therapy beyond symptomatic relief. The firm plans multiple readouts on non-myelofibrosis trials this year, hoping to regain investor confidence amid a cautious marketplace.